Pyrexar Medical In The News

San Francisco, Calif. — March 16, 2005 — Frost & Sullivan will present its 2005 Cancer Therapy Solutions Technology Innovation Award to BSD Medical Corporation at tonight’s second annual Excellence in Medical Devices & Healthcare Awards Banquet.

BSD Medical is recognized for its development of the innovative BSD-2000 Hyperthermia System, which is a cutting-edge cancer therapy that destroys cancer cells effectively and imparts an additive effect when used in combination with existing therapies.

BSD Medical’s hyperthermia systems increase the temperature of cancerous tumors up to 104 to 113 degrees F, selectively killing cancer cells that are particularly vulnerable to destruction by heat. Conventional surface treatment methods do not heat tumors that exist more than a few centimeters below the surface of the skin. Thus, they leave deep tumors unaffected.

"The BSD-2000 technology overcomes such limitations by heating the tumor from inside out, employing a series of patented annular phased-array of radiofrequency antennae that produce energy waves, which pass harmlessly through the body," says Frost & Sullivan research analyst A.N. Aditya. "BSD's technology focuses the energy waves on targeting the site of the tumor specifically."

When the energy waves intersect, enough energy is created to heat the tumor to therapeutic temperatures. Intervening tissues remain unaffected by these waves. Random clinical trials conducted on a variety of cancerous tissues have highlighted the advantage of adding hyperthermia therapy to a standard radiotherapy/chemotherapy regimen. Hyperthermia can even reduce the size of some tumors, making them easier to remove through surgery.

Hyperthermia has proven its efficiency over standard treatments, and the ongoing protocols have marked regional hyperthermia as an essential modality in the prevention and treatment of recurrent and advanced cancer. BSD Medical is the first company to obtain premarket approval from the Food and Drug Administration (FDA) for such a hyperthermia-based cancer therapy system.

"Substantial effort has been put into the development of the BSD-2000 by researchers hailing from top American and European research institutions," observes Aditya. "Additionally, with the support of institutions such as the U.S. National Cancer Institute, further product line enhancements in the form of BSD-2000/3D and BSD-2000/3D/MR have been made."

As a result of all these concentrated R&D activities, BSD-2000/3D can offer three-dimensional steering of deep focused energy, providing greater heating precision to the tumor site. Meanwhile, the BSD-2000/3D/MR includes magnetic resonance imaging (MRI) as an interface with the BSD-2000/3D.

Frost & Sullivan presents its Technology Innovation of the Year Award each year to the company that has excelled in its market by outclassing the competition in all stages of the technology lifecycle – incubation, adoption, take-up, and maturity. By innovating leading-edge concepts, the company has pioneered client applications for the market. The superior technological sophistication has set the company on a growth trajectory in the market.

Held in San Francisco, Frost & Sullivan’s 2005 Excellence in Medical Devices & Healthcare Awards Banquet honors world-class companies for outstanding performance and achievements

in the medical devices industry. An annual event, the banquet recognizes the quality and merit of distinguished individuals and companies.

About BSD Medical Corporation

BSD Medical Corporation is the leading developer of systems used to treat cancer at hyperthermic temperatures using focused electromagnetic energy. The BSD-2000 is used to superheat and kill cancer cells, as well as to boost the effectiveness of radiation and chemotherapy in the effort to improve local control of cancer and increase long-term survival. The BSD-2000 employs a revolutionary annular phased array of radiofrequency (RF) antennae placed around the patient to focus RF energy on tumors, including those located deep in the body. For more information about BSD Medical Corp. and its systems, visit www.BSDMedical.com.

About Frost & Sullivan

Frost & Sullivan, a global growth consulting company, founded in 1961, partners with clients to create value through innovative growth strategies. The foundation of this partnership approach is our Growth Partnership Services platform, whereby we provide industry research, marketing strategies, consulting, and training to our clients to help grow their business. A key benefit that Frost & Sullivan brings to its clients is a global perspective on a broad range of industries, markets, technologies, econometrics, and demographics. With a client list that includes Global 1000 companies, emerging companies, as well as the investment community, Frost & Sullivan has evolved into one of the premier growth consulting companies in the world. For more information, visit www.frost.com.

Contact:
Stacie Jones
210.247.2450

Original Article Link

Maryland Proton Treatment Center Is the Only Facility in World to Offer Both Treatments in Same Location

The Maryland Proton Treatment Center (MPTC) is now offering deep-tissue external thermal therapy in combination with high-precision proton-beam radiotherapy as a potential way to boost survival chances for certain cancer patients. MPTC is the only center in the world to offer these two treatments at the same facility, an advantage to patients because these therapies are typically given within an hour of each other.

Research has shown that thermal therapy can be especially useful in difficult-to-reach cancers in the abdomen and pelvic region. Studies have found that adding thermal therapy to standard treatments can significantly shrink tumors and can improve survival for some patients. External thermal therapy, or hyperthermia – in the range of 104° up to 110° F. – sensitizes tumor cells to chemotherapy and radiation therapy. In addition, heat has been shown to enhance anti-tumor immune response.

“We are very pleased to be able to offer deep-tissue thermal therapy, which can be combined with standard radiation therapy as well as proton-beam therapy to enhance the cancer-killing effects of the radiation,” says Zeljko Vujaskovic, MD, PhD, a professor of radiation oncology and director of the Division of Translational Radiation Sciences (DTRS) in the Department of Radiation Oncology at the University of Maryland School of Medicine (UMSOM).

“Early research suggests that adding thermal therapy to proton-beam therapy may be associated with an even greater benefit than when combined with standard radiation therapy, and we are excited to be at the forefront of making this combination therapy available to cancer patients,” says Dr. Vujaskovic, an internationally recognized expert in hyperthermic oncology.

Proton therapy is a precise form of radiation therapy that deposits all of its energy within the tumor and allows for less irradiation of noncancerous tissue. MPTC – which is affiliated with the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) at the University of Maryland Medical Center – is the only proton treatment center in Maryland.

Radiation oncologists at UMGCCC already use external thermal therapy to treat a range of cancers, but do not currently use it for cancers that are deeper in the body.

According to Dr. Vujaskovic, the new deep-tissue thermal therapy equipment, which is made by Pyrexar, will be used to treat cancers of the abdominal and pelvic region, including cancer of the bladder, rectum, cervix, ovaries, pancreas and connective tissue, which are known as sarcomas. Patients would typically receive the thermal therapy two times a week for an hour before or after they receive standard (photon) radiation or proton-beam therapy.

The system heats the tumor tissue to 108° F. with internal and external probes that enable doctors to continuously monitor the temperature. A water-filled applicator is placed over the area to be treated, and non-invasive radio frequency energy is directed at the tumor. The heat causes the blood vessels in the tumor to dilate, bringing more oxygen into the tumor, which makes cancer cells more vulnerable to radiation therapy.

The acquisition of the deep-tissue thermal therapy system was made possible by donations from Jack and Emily Howell and the Middendorf Foundation, Inc.

“Within the Department of Radiation Oncology and throughout our cancer center, we strive to make every available tool in the cancer-fighting toolbox available to our patients,” says William F. Regine, MD, FACR, FACRO, the Isadore & Fannie Schneider Foxman Endowed Chair and Professor of radiation oncology at UMSOM and chair of radiation oncology at UMGCCC. “By continuing to develop a comprehensive thermal oncology program, we are giving patients more effective treatment options and therefore another reason to hope for better outcomes.”

“The Maryland Proton Treatment Center has achieved another milestone by becoming the first center to offer both deep-thermal therapy and proton therapy,” says E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs at UM Baltimore and the John Z. and Akiko K. Bowers Distinguished Professor and dean at UMSOM. “This achievement is a testament to Dr. Vujaskovic’s considerable expertise in hyperthermic oncology and leadership in developing an outstanding thermal oncology program at the University of Maryland. It’s this type of innovation that sets MPTC apart from other proton treatment centers.”

About the University of Maryland School of Medicine

Commemorating its 211^th Anniversary, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 43 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished recipient of the Albert E. Lasker Award in Medical Research.  With an operating budget of more than $1 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically-based care for more than 1.2 million patients each year. The School has over 2,500 students, residents, and fellows, and nearly $520 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland Baltimore campus, the School of Medicine has a total workforce of nearly 7,000 individuals. The combined School and Medical System (“University of Maryland Medicine”) has an annual budget of nearly $6 billion and an economic impact in excess of $15 billion on the state and local community. The School of Medicine faculty, which ranks as the 8^th-highest public medical school in research productivity, is an innovator in translational medicine, with 600 active patents and 24 start-up companies. The School works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu/

About the Maryland Proton Treatment Center

The Maryland Proton Treatment Center (MPTC) offers proton therapy – a highly advanced and precise form of radiation therapy that can increase radiation dose to tumor while decreasing dose to healthy, surrounding tissue – to the Baltimore/Washington region and beyond. It is a highly effective treatment for a wide range of localized tumors such as those found in the brain, base of the skull, head and neck area, eye tumors, tumors of the esophagus, lung, prostate, liver, breast, spinal cord, as well as gastrointestinal malignancies. It is also an important treatment option for children with cancer.

At MPTC, each treatment room is equipped with the most advanced form of “pencil beam” proton therapy, which essentially paints the radiation onto the tumor while stopping precisely at the site of the tumor. Proton therapy is performed on an outpatient basis and is a well-tolerated, non-invasive treatment that can reduce side effects. It can be used in conjunction with other modalities of cancer treatments such as chemotherapy and surgery. MPTC offers a robust clinical trial program to all its patients to further evidence-based medicine.

MPTC has been patient-centered from the beginning – with a focus on accessibility and affordability. The center was designed to be a regional resource, providing the same training, privileges and clinical guidelines to physician groups across the region that work side-by-side with MPTC faculty and staff, thus improving efficiency and affordability. MPTC offers free concierge services to ensure a seamless patient experience and a successful reconnection back to their referring physician. One of the goals of MPTC is to remain cost-neutral to insurance providers, meaning patients pay the same for proton treatment as they would for other more conventionally available intensity-modulated treatments at the University of Maryland Medical Center. www.mdproton.com.

This article is a press release from the University of Maryland and not an endorsement from Pyrexar Medical

Pyrexar Medical today purchased back all outstanding third party interest in the Utah based corporation.  

In April of 2015, Pyrexar Medical purchased the hyperthermia assets from Perseon Medical, which included the BSD-500 Superficial /Interstitial Hyperthermia System and the BSD-2000 Deep Regional Hyperthermia Systems.  In the original purchase agreement, Perseon Medical maintained a 19.9% interest in Pyrexar, along with royalties on future product sales.

In an agreement reached today, Pyrexar purchased back all Perseon held interests, including all current and future royalty payments. “With the expected growth of Pyrexar Medical, we felt this was a great opportunity to retain full ownership of the company,” said Pyrexar CEO Mark Falkowski. “We should see a significant return on this investment.”

ABOUT PYREXAR MEDICAL:
Pyrexar Medical is a pioneer and worldwide market leader in the development and manufacture of innovative and highly effective thermal therapy/hyperthermia treatment systems with established distribution and support networks around the world. PYREXAR Hyperthermia (PYREXAR HT) treatments, proven in multiple clinical trials over the last 30 years, increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity to healthy tissues.
 
To find out more about Pyrexar Medical products, visit our webpage www.pyrexar.com

Taiwan now treating cancer patients with Hyperthermia in New Taipei City

After passing the rigorous clearance process with the TFDA (Taiwan Food and Drug Administration), a Pyrexar BSD-2000 Deep Regional Hyperthermia system is now installed and treating patients at MacKay Memorial Hospital in New Taipei City, Taiwan. Hyperthermia cancer treatment involves localized heating of cancer tumors using RF energy to a target temperature of 42˚C.  This process is clinically proven to make cancer cells more sensitive to chemotherapy, radiotherapy, and immunotherapy treatments.

On-site to provide hands-on training, and treat the first series of patients, was a well-respected physician and researcher Dr. Jacobi van der Zee from Erasmus University Hospital-Daniel den Hoed Cancer Center Rotterdam, The Netherlands. Dr. van der Zee is recognized as a world leader in hyperthermia with a long list of published papers and clinical studies.

The news quickly reached nearby hospitals creating lines of doctors and clinicians daily to see the new device in action.  Integral to bringing this life-saving treatment to Taiwan was the team from Lindenbiotech and its president Tainang Huang, Ph.D.  “Having this first installation on the island is important to the health and wellbeing of the people of Taiwan,” says Dr. Huang “Cancer is a dire threat to our population which now exceeds 23 million and affects 1 in every 223 people”.  

Mainland China has embraced hyperthermia in the treatment of cancers for over 20 years.  “We are hopeful that this first of several installations planned for Taiwan this year will begin to affect the people of that region positively.,” says Mark Falkowski, CEO Pyrexar Medical. “

ABOUT LINDENBIOTECH:
Lindenbiotech is the exclusive distributor for Pyrexar Hyperthermia products in Taiwan.  Offering site planning, installation, service, and support. lindenbiotech.com

ABOUT PYREXAR MEDICAL:
Pyrexar Medical is a pioneer and worldwide market leader in the development and manufacture of innovative and highly effective thermal therapy/hyperthermia treatment systems with established distribution and support networks around the world. PYREXAR Hyperthermia (PYREXAR HT) treatments, proven in multiple clinical trials over the last 30 years, increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity to healthy tissues.
 
To find out more about Pyrexar Medical products, visit our webpage www.pyrexar.com.

Using hyperthermia to treat disease is not new for the peoples of Spain. Like many European nations, thermal therapy has been in medical practice for some time.  But as the country searches to boost the effectiveness of traditional cancer treatments, it looks toward hyperthermia as the answer.

At a small conference sponsored by the Spanish Societies of Radiation Oncology (SEOR) Hyperthermia Group, an oncologist from the area converged in Málaga, Spain, to talk about a new type of adjunct cancer treatment. They gathered to learn about the positive clinical trials and growing success that surrounds a specific type of thermal therapy, rf (radio frequency) hyperthermia. Energy is directed deep inside the body then focused and steered by adjusting wave frequency and amplitude, resulting in targeted “fever” temperature (41-42C) at the tumor site.  Heat sensitizes and improves blood flow at the tumor site, which, in turn, increases the amount of chemotherapy that reaches inside the tumor. Blood flow also brings oxygen to these hypoxic (without oxygen) cancer tumors, increasing the effectiveness of radiation therapy.  Phase 3 clinical studies demonstrate that hyperthermia, along with chemotherapy or radiotherapy, increases tumor control of up to 300% when compared to radiotherapy or chemotherapy alone.

Thanks to regional groups like the SEOR and companies like Magna Medic, this newest cancer fighter will be available soon. “Facilities, like Clínica Ruber Internacional (Madrid), Vithas Xanit International Hospital (Málaga), Instituto Valenciano de Oncología (Valencia) and Centro Médico Teknon (Barcelona)” are the types of progressive institutions that look for cancer treatment innovations,” says Felix Navarro, Medical Physicist at the Magna Clinic Marbella, “We are very experienced with hyperthermia in our clinic, and we look forward to sharing our successes with the country.”

In preparation for the expected technology growth in the hyperthermia cancer treatment sector, Magna Medic has signed a six-year, $3 million (USD) distribution contract with hyperthermia device maker Pyrexar Medical. “We are excited to see cancer patients get the treatment they deserve,” says Mark Falkowski, Pyrexar CEO, “and we could not find a more capable partner than Magna Medic.”

ABOUT MAGNA MEDIC SYSTEMS:
Based in Málaga, Spain, Magna Medic works in the health sector specializing in technology for oncology groups. A member of SEOR hyperthermia group, the company is currently seeking hyperthermia clinical trials and is a promoter of the university masters of hyperthermia program. See them on the web at www.magnamedic.com.

ABOUT PYREXAR MEDICAL:
Pyrexar Medical is a pioneer and worldwide market leader in the development and manufacture of innovative and highly effective thermal therapy/hyperthermia treatment systems with established distribution and support networks around the world. PYREXAR Hyperthermia treatments, proven in multiple clinical trials over the last 30 years, increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity to healthy tissues. To find out more about Pyrexar Medical products, visit our webpage www.pyrexar.com.

   Dr. Kahled Dabees          Mark FalkowskiAB-Care to distribute Pyrexar Thermal Therapy line.

Salt Lake City, UT– Pyrexar Medical, leaders in thermal therapy systems for cancer treatment, announced that it had signed an exclusive distribution agreement with AB-Care Medical Technology. Based in Cairo, Egypt, AB-Care provides a wide array of medical equipment and supplies to the region via offices in Alexandria, Mansoura, Cairo, and Assiut. This agreement represents a $3 million commitment to the hyperthermia product line over the next six years.

The first written reference to hyperthermia is found in an Egyptian papyrus scroll dating over 5000 years ago. Hyperthermia, also known as thermal therapy, is clinically proven to boost the effectiveness of radiation therapy and chemotherapy in cancer patients. Thermal therapy works by increasing blood flow and oxygenation to the tumor site.  As an adjunct therapy to radiation treatment, hyperthermia increases the number of oxygen radicals that can be produced to destroy cancer cells.  When used with chemotherapy, thermal therapy treatments sensitize the tumor site allowing more cancer-killing agents to target the tumor.

Dr. Kahled Dabees, Managing Director of AB-Care Medical Technology, debuted the Pyrexar product line at the Arab Health Show in Dubai this week.  Arab Health is the largest medical products show in the region attracting approx. 110,000 visitors.  “We are proud to have such a cutting edge medical technology to offer to the country,” said Dr. Dabees. “Like many countries in the region, cancer takes its toll on our population.  We strive to lead the region in superior cancer treatment technologies.”

“This year, the Pyrexar team has worked at a tremendous pace to bring hyperthermia to the worldwide medical community,” said Mark Falkowski, CEO of Pyrexar Medical. “We are dedicated to this therapy, and we believe that the AB-Care partnership, along with their dedicated staff, will help us achieve our goals. Once you see the clinical data, there is no way to deny the tremendous benefit hyperthermia can provide to cancer patients.”

ABOUT AB-CARE MEDICAL TECHNOLOGY
Headquartered in Cairo, Egypt, the company was established in 2011 by tycoon medical equipment distributor KSA (Banaja Holding). The goal of the company is to be the leader in the Egyptian Healthcare Industry by building a strong commitment to the region, targeting innovation, and conducting business with the highest code of ethics. More at www.ab-care.com

ABOUT PYREXAR MEDICAL:
Pyrexar Medical is a pioneer and worldwide market leader in the development and manufacture of innovative and highly effective thermal therapy/hyperthermia treatment systems with established distribution and support networks around the world. PYREXAR HyperThermia (PYREXAR HT) treatments, proven in multiple clinical trials over the last 30 years, increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity to healthy tissues.

To find out more about Pyrexar Medical products, visit our webpage www.pyrexar.com.

Salt Lake City, UT– Pyrexar Medical, leaders in thermal therapy systems, exhibited at the Radiological Society of North America (RSNA) Annual Meeting held last week in Chicago’s McCormick Place.

Pyrexar showcased their line of superficial, interstitial and deep regional hyperthermia systems for the treatment of cancer. Touted at the world’s largest medical device conference, the RSNA attracted radiology professionals from around the world.

Distributors from all over the world use the RSNA to learn about new technologies and to add devices to their product offering.  “I have been attending RSNA for over thirty years”, says Mark Falkowski, CEO at Pyrexar Medical.  “The relationships and introductions you make at the show are a very important part of our total marketing and sales strategy.” This year was no different as distributors from over 30 countries were in the Pyrexar booth vying for the hyperthermia line.

In a related conference event, Mark Dewhirst, DVM, PhD from Duke University Medical Center presented "Lessons Learned from XRT/Hyperthermia”.   In his presentation Dr. Dewhirst explained how hyperthermia compliments the ability of radiotherapy to kill cancer cells and reviewed the more than a dozen positive phase III cancer trials where hyperthermia was used in conjunction with radiotherapy.  He also provided new insights on how hyperthermia affects the process of DNA damage repair.

This was Pyrexar Medical’s first year at RSNA and space has already been reserved for next year’s conference in Boston.

ABOUT PYREXAR MEDICAL:
Pyrexar Medical is a pioneer and worldwide market leader in the development and manufacture of innovative and highly effective thermal therapy/hyperthermia treatment systems with established distribution and support networks around the world. PYREXAR HyperThermia (PYREXAR HT) treatments, proven in multiple clinical trials over the last 30 years, increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity to healthy tissues.

Hyperthermia PLUS Proton Therapy Cancer Treatment

This year’s “Workshop on Hadron Therapy” was hosted by the Mesoamerican Center for Theoretical Physics (MCTP) and FIMENUTEP (Nuclear and Medical Physics Proton Therapy) in Tuxtla Gutierrez in the state of Chiapas, Mexico.  The three-day summit brought together experts from around the world to discuss the benefits and implementation of proton therapy in the treatment of cancer.  Presenters included the Mayo Clinic, University Hospital of Geneva, John Hopkins School of Medicine and Benemérita Universidad Autónoma de Puebla (BUAP).

Mark Falkowski, CEO at Pyrexar Medical, was invited as the industry leader in thermal therpay medical devices to present the topic “Hyperthermia for Proton Therapy”.  Interest in the combined therapy was generated by a paper published in 2014 by N. Datta entitled, “Could hyperthermia with proton therapy mimic carbon ion therapy?”  This research is important as it postulates that not only could adding hyperthermia to proton therapy increase the effectiveness, but also potentially mimic the superior results of carbon ion therapy without the magnitude higher systems cost.

Currently, there is a multi-institutional phase I/II clinical trial with concomitant local hyperthermia and proton beam radiotherapy at the Kantonsspital Aarau in Switzerland. Hyperthermia is a well-known sensitizer of cancer tumors, increasing tumor response and increasing effective dose in radiation therapy.  Researchers have measured increases in tumor control and complete response in many cancers when adding hyperthermia to chemotherapy and traditional radiotherapy. The new study is designed to measure the effective increase when adding hyperthermia to proton therapy.
 
The Hadron Therapy Workshop provided another opportunity to share the hyperthermia message with medical experts, staff and university researchers focused on increasing the effectiveness of cancer treatments. Pyrexar Medical continues to ask the question, “If there is a pain-free, harm-free way to increase cancer survival rates, why not choose to use it?”

ABOUT PYREXAR MEDICAL:
Pyrexar Medical is a pioneer and worldwide market leader in the development and manufacture of innovative and highly effective thermal therapy/hyperthermia treatment systems with established distribution and support networks around the world. PYREXAR HyperThermia (PYREXAR HT) treatments, proven in multiple clinical trials over the last 30 years, increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity to healthy tissues.

Salt Lake City, UT– Pyrexar Medical, leaders in thermal therapy systems, will be exhibiting at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting held in San Antonio’s Henry B. Gonzalez Convention Center on October 18-20,2015.

Pyrexar will showcase their line of superficial, interstitial and deep regional hyperthermia systems for the treatment of cancer. Clinical studies confirm that hyperthermia added to radiotherapy boosts effective dose and increases response rate without any cumulative damage to healthy tissues. Thermal Therapy is one of the most important new cancer therapies on the market and it is under-represented in the U.S.  Pyrexar will be the only manufacturer of this technology exhibiting at the show.

It has been a very big year for the newly formed Pyrexar. Since purchasing the assets from the 30-year-old device manufacturer BSD Medical, the company has experienced phenomenal growth. This growth coincides with important clinical findings supporting the use of thermal therapy, aka hyperthermia, to treat cancer. The most recent peer review (published in Cancer Treatment Reviews) of 38 clinical studies, including cancers of the bladder, breast, cervical, esophageal, head & neck, pediatric tumors, rectal and soft tissue sarcoma, concludes that adding hyperthermia to traditional cancer treatment improves outcomes by an average of 1.8.

“There is no better time to talk about the benefits of thermal therapy than now”, says Mark Falkowski, CEO at Pyrexar Medical.  “We are seeing an improvement in outcomes by adding a pain-free, harm-free treatment protocol to the standard of care.  Why wouldn’t you give that to a loved one if it could mean more time.” Pyrexar will be launching its #OneMoreYear campaign at the show, challenging everyone to think about what they would do if given one more year.

You can find Pyrexar at booth 1753 at the ASTRO show October 18, 19 & 20 and later this year at RSNA Nov. 29th - Dec 4th in Chicago. To learn more about Pyrexar products and be part of the #OneMoreYear campaign, visit www.pyrexar.com.

ABOUT PYREXAR MEDICAL:
Pyrexar Medical is a pioneer and worldwide market leader in the development and manufacture of innovative and highly effective thermal therapy/hyperthermia treatment systems with established distribution and support networks around the world. PYREXAR HyperThermia (PYREXAR HT) treatments, proven in multiple clinical trials over the last 30 years, increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity to healthy tissues.

Pyrexar Medical, leaders in thermal therapy systems for cancer treatment, announced that it has signed an exclusive distribution agreement with Magna Medic Systems of Spain.

Magna Medic Systems is an ESHO (European Society of Hyperthermic Oncology) partner and the driving force behind the creation of the thermal oncology working group of SEOR (Spanish Society of Radiation Oncology). SEOR is a group of 60 oncologists looking to improve cancer treatment outcomes with the latest in cancer fighting technologies.

Hyperthermia, also known as thermal therapy, is clinically proven to boost the effectiveness of radiation therapy and chemotherapy in cancer patients. Thermal therapy works by increasing blood flow and oxygenation to the tumor site.  As an adjunct therapy to radiation treatment, hyperthermia increases the number of oxygen radicals that can be produced to destroy cancer cells.  When used with chemotherapy, thermal therapy treatments sensitize the tumor site allowing more cancer killing agents to target the tumor.

According to Magna Medic general manager Elie Helou, the company has three main objectives in bringing thermal therapy to the country. 1) To improve the quality of life for those who are affected by cancer; 2) to educate the oncology community of the increased survival benefits when combining hyperthermia with radiation therapy and chemotherapy; 3) provide the best in hyperthermia technology and education to the oncology community and their patients. “After extensive market evaluation, we chose Pyrexar to help us achieve our goals,” says Mr. Helou. “We look forward to making an impact in the marketplace”.

“We are pleased to have the caliber of people at Magna Medic working with us.” said Mark Falkowski, CEO of Pyrexar Medical. “Their dedication and passion to improve cancer outcomes meshes well with our goals at Pyrexar. With their help, we will continue to promote the use of hyperthermia in Spain and throughout the region.”

ABOUT MAGNA MEDIC SYSTEMS:
Based in Málaga, Spain, Magna Medic works in the health sector specializing in technology for oncology groups. A member of SEOR hyperthermia group, the company is currently seeking hyperthermia clinical trials and is a promoter of the university masters of hyperthermia program. See them on the web at www.magnamedic.com

ABOUT PYREXAR MEDICAL:
Pyrexar Medical is a pioneer and worldwide market leader in the development and manufacture of innovative and highly effective thermal therapy/hyperthermia treatment systems with established distribution and support networks around the world. PYREXAR HyperThermia (PYREXAR HT) treatments, proven in multiple clinical trials over the last 30 years, increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity to healthy tissues.

To find out more about Pyrexar Medical products, visit our webpage www.pyrexar.com.